Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedDec 10, 2025
DataAggregated Company Financials
Companies4
  • 7D-0.9%
  • 3M19.9%
  • 1Y27.0%
  • YTD24.9%

The Biotech is pretty flat in the last 7 days, but Idorsia has stood out, gaining 17%. The past year has been better, since the industry has gained 33% in that time. Earnings are forecast to grow by 29% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 10 Dec 2025CHF 2.0bCHF 343.6m-CHF 10,514,000.008.7x-186.9x5.7x
Fri, 07 Nov 2025CHF 1.8bCHF 343.6m-CHF 10,514,000.007.6x-172.3x5.3x
Sun, 05 Oct 2025CHF 1.9bCHF 344.3m-CHF 15,083,000.008.2x-123.2x5.4x
Tue, 02 Sep 2025CHF 1.9bCHF 383.4m-CHF 57,057,000.007.9x-32.5x4.8x
Thu, 31 Jul 2025CHF 2.2bCHF 333.9m-CHF 44,705,000.009.1x-48.8x6.5x
Sat, 28 Jun 2025CHF 2.0bCHF 333.9m-CHF 44,705,000.007.5x-43.7x5.9x
Mon, 26 May 2025CHF 1.8bCHF 333.9m-CHF 44,705,000.007x-40.2x5.4x
Wed, 23 Apr 2025CHF 1.6bCHF 411.1mCHF 65.6m4.6x24.9x4x
Fri, 21 Mar 2025CHF 1.7bCHF 409.3m-CHF 35,110,868.005.2x-47.6x4.1x
Sun, 16 Feb 2025CHF 2.0bCHF 327.8m-CHF 127,073,868.003.3x-15.4x6x
Tue, 14 Jan 2025CHF 1.8bCHF 330.3m-CHF 75,131,868.002.5x-23.4x5.3x
Thu, 12 Dec 2024CHF 1.7bCHF 330.9m-CHF 87,805,465.001.9x-19x5x
Sat, 09 Nov 2024CHF 1.9bCHF 331.2m-CHF 86,988,629.001.7x-22.4x5.9x
Mon, 07 Oct 2024CHF 1.5bCHF 333.1m-CHF 82,023,629.001.7x-18.7x4.6x
Wed, 04 Sep 2024CHF 1.5bCHF 323.4m-CHF 89,161,264.002x-16.8x4.6x
Fri, 02 Aug 2024CHF 799.5mCHF 151.7m-CHF 146,197,264.001.6x-5.5x5.3x
Sun, 30 Jun 2024CHF 755.7mCHF 151.7m-CHF 146,197,264.001.4x-5.2x5x
Tue, 28 May 2024CHF 545.0mCHF 170.5m-CHF 131,456,924.261x-4.1x3.2x
Thu, 25 Apr 2024CHF 392.0mCHF 67.2m-CHF 172,299,290.500.07x-2.3x5.8x
Sat, 23 Mar 2024CHF 340.9mCHF 67.3m-CHF 173,226,506.340.2x-2x5.1x
Mon, 19 Feb 2024CHF 398.9mCHF 55.5m-CHF 173,229,467.361x-2.3x7.2x
Wed, 17 Jan 2024CHF 342.3mCHF 317.6m-CHF 176,008,605.000.5x-1.9x1.1x
Fri, 15 Dec 2023CHF 296.7mCHF 317.6m-CHF 208,646,316.00n/a-1.4x0.9x
Sun, 12 Nov 2023CHF 292.3mCHF 318.5m-CHF 211,286,620.00n/a-1.4x0.9x
Tue, 10 Oct 2023CHF 249.3mCHF 318.4m-CHF 213,277,782.00n/a-1.2x0.8x
Thu, 07 Sep 2023CHF 318.1mCHF 318.6m-CHF 188,937,509.00n/a-1.7x1x
Sat, 05 Aug 2023CHF 528.8mCHF 323.7m-CHF 180,004,478.00n/a-2.9x1.6x
Mon, 03 Jul 2023CHF 302.2mCHF 330.6m-CHF 180,777,833.00n/a-1.7x0.9x
Wed, 31 May 2023CHF 317.9mCHF 332.7m-CHF 183,365,217.00n/a-1.7x1x
Fri, 28 Apr 2023CHF 355.7mCHF 498.9m-CHF 18,572,349.001.6x-19.2x0.7x
Sun, 26 Mar 2023CHF 426.5mCHF 497.1mCHF 11.5m1.5x37x0.9x
Tue, 21 Feb 2023CHF 480.7mCHF 493.4mCHF 14.5m1.6x33.1x1x
Thu, 19 Jan 2023CHF 524.9mCHF 493.4mCHF 14.5m1.8x36.2x1.1x
Sat, 17 Dec 2022CHF 500.1mCHF 493.4mCHF 14.5m1.7x34.5x1x
Price to Earnings Ratio

34.5x


Total Market Cap: CHF 500.1mTotal Earnings: CHF 14.5mTotal Revenue: CHF 493.4mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average -18x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 3.5x is lower than the industry's current PS ratio of 5.8x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 11% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.36%
Healthcare0.73%
Biotech-0.91%
Biotech-0.91%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
IDIA IdorsiaCHF 3.853.5%
+CHF 32.5m		187.6%PS4.1x
BSLN Basilea PharmaceuticaCHF 51.504.5%
+CHF 27.0m		25.0%PE8.7x
SANN Santhera Pharmaceuticals HoldingCHF 12.421.8%
+CHF 2.9m		38.0%PS3.4x
MOLN Molecular PartnersCHF 3.282.0%
+CHF 2.4m		-35.1%PB1.3x
RLF Relief Therapeutics HoldingCHF 2.905.1%
+CHF 1.8m		-22.7%PS9x

Latest News

IDIA
CHF 3.85
Idorsia
7D
3.5%
1Y
187.6%

IDIA: Hypertension And Insomnia Portfolio Will Likely Fail To Justify Current Price

Analysts have modestly raised their price target on Idorsia, citing a slightly lower perceived risk profile and a marginally stronger long term profit outlook that supports a small increase in fair value, now estimated at approximately 2.00. What's in the News Reaffirmed 2025 guidance, projecting QUVIVIQ net sales around CHF 130 million, partnered business US-GAAP EBIT of about CHF 165 million, and a global US-GAAP operating loss of roughly CHF 55 million, mainly driven by the amended Viatris deal (corporate guidance).
SANN
CHF 12.42
Santhera Pharmaceuticals Holding
7D
1.8%
1Y
38.0%
MOLN
CHF 3.28
Molecular Partners
7D
2.0%
1Y
-35.1%
BSLN
CHF 51.50
Basilea Pharmaceutica
7D
4.5%
1Y
25.0%
KURN
CHF 29.96
Kuros Biosciences
7D
-4.0%
1Y
45.8%

Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts

Oct 18
Kuros Biosciences AG's (VTX:KURN) Sole Analyst Just Made A Notable Upgrade To Their Forecasts
RLF
CHF 2.90
Relief Therapeutics Holding
7D
5.1%
1Y
-22.7%